Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Safety Meta-Analysis Trumped By Long, Large Trial At Spiriva Advisory Panel

Executive Summary

A clinical trial trumps a meta-analysis for assessing drug safety, at least when it's large and well-done - that was the message from FDA's Pulmonary-Allergy Drugs Advisory Committee during its review of an additional indication for Boehringer Ingelheim's Spiriva HandiHaler Nov. 19

You may also be interested in...

Boehringer’s Tiotropium Spray May Be Ready To Shed Mortality Issues

FDA Pulmonary-Allergy Drugs Advisory Committee to review NDA for COPD and will discuss safety results from trial comparing inhalation spray to powder.

Boehringer’s Olodaterol Will Have To Pass LABA Hurdles At January Advisory Committee

Boehringer Ingelheim’s long acting beta-adrenergic agonist for chronic obstructive pulmonary disease will have to overcome LABA class issues in asthma at an advisory committee in January. The drug is up first for single-agent approval, but it is meant to be half of a combination therapy with the blockbuster treatment Spiriva.

FDA Clears Spiriva HandiHaler Of Increased Cardiovascular Risk

Two years after an Early Communication about potential risk and two years months after an advisory gave it the thumbs ups, Boehringer Ingleheim's COPD therapy gets an official FDA announcement that it does not appear to be linked to increased CV events.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts